@article{b3ee0ecb0bed4481a92e483e88925743,
title = "Efficacy of Ibandronate Loading Dose on Rapid Pain Relief in Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: The NVALT-9 Trial",
abstract = "Introduction:Approximately 80% of non-small cell lung cancer (NSCLC) patients with bone metastases have cancer induced bone pain (CIBP). Methods:The NVALT-9 was an open-label, single arm, phase II, multicenter study. Main inclusion criterion: bone metastasized NSCLC patients with uncontrolled CIBP [brief pain inventory [BPI] >= 5 over last 7 days]. Patients were treated with six milligram ibandronate intravenously (day 1-3) once a day. Main exclusion criteria: active secondary malignancy, systemic anti-tumor treatment and radiotherapy = 80% and 95% confidence to declare the treatment inactive if the pain response rate is",
keywords = "carcinoma, non-small-cell lung, pain management, cancer induced bone pain, clinical trials, phase II as topic, ibandronic acid, QUALITY-OF-LIFE, SKELETAL METASTASES, BISPHOSPHONATES, DISEASE",
author = "Brouns, {Anita J. W. M.} and Hendriks, {Lizza E. L.} and {van Der Noort}, Vincent and {van de Borne}, {Ben E. E. M.} and Schramel, {Franz M. N. H.} and Groen, {Harry J. M.} and Bonne Biesma and Smit, {Hans J. M.} and Dingemans, {Anne-Marie C.}",
note = "Funding Information: Funding. The authors declare that this study received funding from Roche, and that Ibandronate was supplied by Roche. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2020 Brouns, Hendriks, van der Noort, van de Borne, Schramel, Groen, Biesma, Smit and Dingemans.",
year = "2020",
month = jun,
day = "24",
doi = "10.3389/fonc.2020.00890",
language = "English",
volume = "10",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media SA",
}